Safety, tolerability and pharmacokinetics of crizotinib in combination with cytotoxic chemotherapy for pediatric patients with refractory solid tumors or anaplastic large-cell lymphoma (ALCL): A Children’s Oncology Group phase 1 consortium study (ADVL1212)

PURPOSE: This phase 1 study aimed to determine the safety, tolerability and recommended phase 2 dose (RP2D) of crizotinib in combination with cytotoxic chemotherapy for children with refractory solid tumors and ALCL. METHODS: Pediatric patients with treatment refractory solid tumors or ALCL were eli...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer Chemother Pharmacol
Main Authors: Greengard, Emily, Mosse, Yael P, Liu, Xiaowei, Minard, Charles G., Reid, Joel M., Voss, Stephan, Wilner, Keith, Fox, Elizabeth, Balis, Frank, Blaney, Susan M., Adamson, Peter C, Weigel, Brenda J
Formato: Artigo
Idioma:Inglês
Publicado em: 2020
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7757912/
https://ncbi.nlm.nih.gov/pubmed/33095287
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-020-04171-4
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados